Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Anemia |
| Online Access: | http://dx.doi.org/10.1155/2012/297641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563119373680640 |
|---|---|
| author | John Porter Donald K. Bowden Marina Economou Jacques Troncy Arnold Ganser Dany Habr Nicolas Martin Adam Gater Diana Rofail Linda Abetz-Webb Helen Lau Maria Domenica Cappellini |
| author_facet | John Porter Donald K. Bowden Marina Economou Jacques Troncy Arnold Ganser Dany Habr Nicolas Martin Adam Gater Diana Rofail Linda Abetz-Webb Helen Lau Maria Domenica Cappellini |
| author_sort | John Porter |
| collection | DOAJ |
| description | Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (n=274) and myelodysplastic syndrome (MDS) patients (n=168) patients participating in the Evaluation of Patients' Iron Chelation with Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study investigating the efficacy and safety of the once-daily oral iron chelator, deferasirox. HRQOL and satisfaction, adherence, and persistence to iron chelation therapy (ICT) data were collected at baseline and end of study using the Medical Outcomes Short-Form 36-item Health Survey (SF-36v2) and the Satisfaction with ICT Questionnaire (SICT). Compared to age-matched norms, β-thalassemia and MDS patients reported lower SF-36 domain scores at baseline. Low levels of treatment satisfaction, adherence, and persistence were also observed. HRQOL improved following treatment with deferasirox, particularly among β-thalassemia patients. Furthermore, patients reported high levels of satisfaction with deferasirox at end of study and greater ICT adherence, and persistence. Findings suggest deferasirox improves HRQOL, treatment satisfaction, adherence, and persistence with ICT in β-thalassemia and MDS patients. Improving such outcomes is an important long-term goal for patients with iron overload. |
| format | Article |
| id | doaj-art-dc0eaa16090e46b9adb84445dd17e8bb |
| institution | Kabale University |
| issn | 2090-1267 2090-1275 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anemia |
| spelling | doaj-art-dc0eaa16090e46b9adb84445dd17e8bb2025-02-03T01:21:01ZengWileyAnemia2090-12672090-12752012-01-01201210.1155/2012/297641297641Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical TrialJohn Porter0Donald K. Bowden1Marina Economou2Jacques Troncy3Arnold Ganser4Dany Habr5Nicolas Martin6Adam Gater7Diana Rofail8Linda Abetz-Webb9Helen Lau10Maria Domenica Cappellini11Department of Haematology, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UKMonash Medical Centre, Melbourne, VIC 3168, AustraliaThalassemia Clinical Care Services Unit, Hippokration General Hospital Thessaloniki, Egnatia Street 106, 54622 Thessaloniki, GreeceHematology, Hopital Edouard Herriot, 6 Rue Antoine Lumiere, 69008 Lyon, FranceMedizinische Hochschule Hannover (MHH), Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Carl-Neuberg Strasse 1, 30625 Hannover, GermanyNovartis Pharmaceutical Corporation, 180 Park Avenue, 105-3E065, Florham Park, NJ 07932-1080, USANovartis Pharma AG Postfach, 4002 Basel, SwitzerlandAdelphi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UKAdelphi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UKAdelphi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UKNovartis Pharmaceutical Corporation, 180 Park Avenue, 105-3E065, Florham Park, NJ 07932-1080, USAUniversita di Milano, Can Granda Foundation IRCCS, Via F. Sforza 35, 20122 Milan, ItalyTreatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (n=274) and myelodysplastic syndrome (MDS) patients (n=168) patients participating in the Evaluation of Patients' Iron Chelation with Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study investigating the efficacy and safety of the once-daily oral iron chelator, deferasirox. HRQOL and satisfaction, adherence, and persistence to iron chelation therapy (ICT) data were collected at baseline and end of study using the Medical Outcomes Short-Form 36-item Health Survey (SF-36v2) and the Satisfaction with ICT Questionnaire (SICT). Compared to age-matched norms, β-thalassemia and MDS patients reported lower SF-36 domain scores at baseline. Low levels of treatment satisfaction, adherence, and persistence were also observed. HRQOL improved following treatment with deferasirox, particularly among β-thalassemia patients. Furthermore, patients reported high levels of satisfaction with deferasirox at end of study and greater ICT adherence, and persistence. Findings suggest deferasirox improves HRQOL, treatment satisfaction, adherence, and persistence with ICT in β-thalassemia and MDS patients. Improving such outcomes is an important long-term goal for patients with iron overload.http://dx.doi.org/10.1155/2012/297641 |
| spellingShingle | John Porter Donald K. Bowden Marina Economou Jacques Troncy Arnold Ganser Dany Habr Nicolas Martin Adam Gater Diana Rofail Linda Abetz-Webb Helen Lau Maria Domenica Cappellini Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial Anemia |
| title | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial |
| title_full | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial |
| title_fullStr | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial |
| title_full_unstemmed | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial |
| title_short | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial |
| title_sort | health related quality of life treatment satisfaction adherence and persistence in β thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox results from the epic clinical trial |
| url | http://dx.doi.org/10.1155/2012/297641 |
| work_keys_str_mv | AT johnporter healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT donaldkbowden healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT marinaeconomou healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT jacquestroncy healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT arnoldganser healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT danyhabr healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT nicolasmartin healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT adamgater healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT dianarofail healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT lindaabetzwebb healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT helenlau healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial AT mariadomenicacappellini healthrelatedqualityoflifetreatmentsatisfactionadherenceandpersistenceinbthalassemiaandmyelodysplasticsyndromepatientswithironoverloadreceivingdeferasiroxresultsfromtheepicclinicaltrial |